Trial Profile
Development of a Polyvalent Vaccine Against Enterotoxigenic Escherichia Coli (ETEC)Protective Efficacy of the Deletion-Attenuated, Multi-valent ACE527 Against Challenge With a Prototype Strain of Enterotoxigenic E.Coli Expressing LT and ST Enterotoxins and CFA/I (Strain H10407) in Human Challenge Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2015
Price :
$35
*
At a glance
- Drugs ACE 527 (Primary)
- Indications Diarrhoea; Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
- Focus Therapeutic Use
- Sponsors TD Vaccines A/S
- 06 Dec 2010 Results presented in a TD vaccines A/S media release
- 06 Dec 2010 Status changed from recruiting to completed.
- 31 Mar 2010 Actual initiation date (Mar 2010) added as reported by ClinicalTrials.gov.